CompletedNot Applicable

Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH

France176 participantsStarted 2015-02

Plain-language summary

In a population of patients with Non Alcoholic Fatty Liver Disease (NAFLD), the investigators will compare the composition of the gut microbiota from patients with simple steatosis with that with steatohepatitis. The purpose of this study is to determine if the pathogenic Escherichia Coli to the B2 group and producing the genotoxin colibactin is a factor for developing NASH.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * NAFLD * indication of liver biopsy Exclusion Criteria: * presence of any other cause of liver or steatosis * alcohol consumption exceeding 30 g / day for a men and 20 g / day for a woman * a history of decompensated cirrhosis * treatment with prebiotics, probiotics or antibiotics in the month prior to inclusion * chronic gastrointestinal disease or history of gastrointestinal surgery * pregnancy or breastfeeding * patient under guardianship

What they're measuring

composition of the gut microbiota between two groups, and prevalence of the Escherichia Coli belonging to the B2 group and producing the genotoxin colibactin.

Timeframe: 1 day

Trial details

NCT IDNCT02390232

SponsorUniversity Hospital, Toulouse

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-11

View on ClinicalTrials.gov More Non-alcoholic Fatty Liver Disease trials